Stocktoria
Grace Therapeutics, Inc. GRCE
Grace Therapeutics, Inc. (GRCE) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.229 |
| Retained earnings / assets | -3.428 |
| EBIT / assets | -0.166 |
| Equity / liabilities | 23.168 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| GRCE | Grace Therapeutics, Inc. | 1/9 | 13.53 | — | — |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
FAQ
Is GRCE financially healthy?
Grace Therapeutics, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does GRCE pay a dividend?
No, Grace Therapeutics, Inc. does not currently pay a dividend.
How profitable is GRCE?
In FY2026, Grace Therapeutics, Inc. had a return on equity of -12.2%.
What is the analyst price target for GRCE?
The average Wall-Street price target for Grace Therapeutics, Inc. is $5.95, about 183.2% above the recent price, from 2 analysts (consensus: strong buy).
Is GRCE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Grace Therapeutics, Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.